Exhibit 99.1

LOGO

FOR IMMEDIATE RELEASE

 

Contacts:    Urologix:
   Fred B. Parks, Chairman and CEO
   Elissa J. Lindsoe, CFO
   (763) 475-1400

UROLOGIX REPORTS FOURTH QUARTER AND FISCAL 2007 RESULTS

MINNEAPOLIS—August 22, 2007—Urologix

®, Inc. (NASDAQ:ULGX), today reported financial results for the fiscal 2007 fourth quarter and year ended June 30, 2007, both of which include $4.8 million in non-cash income tax expense to increase the tax valuation allowance to fully reserve the Company’s deferred tax assets and a $6.4 million non-cash charge for long lived asset impairments and inventory write-downs for a total in non-cash charges of $11.2 million.

Revenue for the fourth quarter was $4.8 million compared to $5.1 million reported in the third quarter of fiscal 2007 and $6.6 million in the fourth quarter of fiscal 2006. For the fourth quarter of fiscal 2007, revenue from catheter sales to direct accounts declined 6% from the third quarter of fiscal 2007, driven primarily by a reduction in average selling price. Revenue from catheter sales to direct accounts constituted 51% of overall revenue in the fourth quarter of 2007 as compared to 52% in the prior quarter. Third party mobile revenue represented approximately 9% of overall revenue in both the fourth and third quarters of fiscal 2007. Sales of Urologix-owned Cooled ThermoTherapy mobile service treatments declined 2% compared to the third quarter of fiscal 2007, constituting 37% of overall revenue in the fourth quarter of 2007 compared to 36% in the prior quarter.

The net loss for the fourth quarter was $12.1 million, or $0.84 per diluted share. Impacting the fourth quarter net loss were non-cash long lived asset impairment charges, inventory write-downs and income tax expense recorded in the fourth quarter totaling $11.2 million, or $0.78 per diluted share. This compares to a net loss of $0.8 million, or $0.05 per diluted share, in the third quarter of fiscal 2007 and net earnings of $4.7 million, or $0.32 per diluted share, which includes $4.6 million, or $0.32 per diluted share, income tax benefit, in the fourth quarter of fiscal 2006 to reduce the valuation allowance related to the Company’s deferred tax asset.


The following information was filed by Urologix Inc (ULGX) on Thursday, August 23, 2007 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Urologix Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Urologix Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account